At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
lenvatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors
In Brief
A Phase 1 clinical trial evaluating lenvatinib and pembrolizumab for Solid Tumors. Completed, enrolled 6 participants across 1 site.
Detailed Summary
This is an open-label Phase 1b study designed to confirm the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with selected solid tumors (non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma \[excluding uveal melanoma\]).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesJapan
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJan 2017
Primary CompletionApr 2020
TodayJul 2026
First PostedDec 30, 2016
Enrollment StartJan 12, 2017
Primary CompletionApr 15, 2020
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.5 years ago
Interventions
lenvatinibdrug
lenvatinib capsules
pembrolizumabdrug
pembrolizumab intravenous infusion